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2Abstract30
31
Context  Survivors of childhood cancer are at increased risk of premature mortality 32
compared to the general population, but little is known about the long-term risks of specific 33
causes of death, particularly beyond 25 years from diagnosis at ages when the background 34
mortality in the general population starts to increase substantially.  35
Objective  To investigate long-term cause-specific mortality in a cohort with over three times 36
the number of person-years and deaths beyond 25 years from diagnosis than previously 37
available. 38
Design, Setting, and Patients  British Childhood Cancer Survivor Study, a population-39
based cohort of 17,981 5-year survivors of childhood cancer diagnosed with cancer before 40
age 15 years, between 1940 and 1991, in Britain. 41
Main outcome measures  Cause-specific standardized mortality ratios (SMR) and absolute 42
excess risks (AER).43
Results   Overall, 3,049 deaths were observed, which was 11-times (SMR=10.7; 95%CI: 44
10.3-11.1) the number expected. The SMR declined with follow-up, but was still 3-fold 45
expected (SMR=3.1, 95%CI: 2.5-3.9) 45 years from diagnosis. The AER for deaths from 46
recurrence declined from 97 extra deaths (per 10,000 per year) at 5-14 years from 47
diagnosis, to 8 extra deaths beyond 45 years from diagnosis. In contrast, during the same 48
periods of follow-up the AER for deaths from second primary cancer and circulatory causes 49
increased from 8 and 2 extra deaths to 58 and 29 extra deaths, respectively. Beyond 45 50
years from diagnosis recurrence only accounts for 7% of the excess number of deaths 51
observed whilst second primary cancer and circulatory deaths together account for 77%.  52
Conclusion  These results indicate that considerable numbers of survivors are dying 53
prematurely from second primary cancer and circulatory disease beyond 25 years from 54
diagnosis. Survivors should therefore be able to access health care programmes even 55
decades from treatment.56
3Introduction57
Over recent decades survival from childhood cancer has improved dramatically; yet, 58
mortality rates in childhood cancer survivors continue to be elevated for many years beyond 59
five-year survival compared to the general population.1 Previous studies have shown that the 60
leading cause of death following five-year survival is recurrence or progression of the original 61
tumor, followed by second primary cancer and non-neoplastic conditions such as cardiac 62
disease.2-8 Although studies have shown that the risk of death from recurrence decreases 63
with increasing time since five-year survival, the uncertainty about the long-term risks of 64
death from other causes remains. Investigations into long-term cause specific mortality are 65
important as any excess mortality may be related to long-term complications of treatment. 66
Strongly elevated mortality risks related to second primary cancer and non-neoplastic 67
disease, when compared to the general population, have been reported over the first 20 68
years after 5-year survival.2-5 However, it is largely unknown whether these increased risks 69
persist beyond 25 years from initial cancer diagnosis, at ages when the background mortality 70
in the general population starts to increase substantially. Previous studies had insufficient 71
person-years and observed deaths beyond 25 years from diagnosis to satisfactorily 72
investigate long-term cause-specific mortality. With increasing numbers of survivors now 73
reaching mature adulthood, an elevated relative risk of common chronic diseases of mature 74
adulthood sustained into old age would greatly increase the absolute number of survivors 75
who ultimately die prematurely. 76
The main objective of this study was to investigate long-term cause-specific mortality 77
within a large-scale population-based cohort with more than four times the number of 78
person-years and three times the number of deaths beyond 25 years from initial cancer 79
diagnosis than previously available to the largest of all previous studies.2 We report mortality 80
risks up to 55 years after diagnosis of the initial childhood cancer; 20 years longer than 81
previously reported by any other large-scale study.  82
83
4Subjects and Methods 84
British Childhood Cancer Survivor Study 85
The British Childhood Cancer Survivor Study (BCCSS) is the largest population-based 86
cohort study to comprehensively examine the late-effects of childhood cancer and its 87
treatment. The study comprises 17,981 five-year survivors of childhood cancer diagnosed 88
under the age of 15 years between 1940 and 1991 in Britain.9 The cohort was ascertained 89
through the National Registry of Childhood Tumours which is maintained by the Childhood 90
Cancer Research Group (CCRG) at the University of Oxford. Information on type of 91
childhood cancer, initial treatment (i.e., radiotherapy, chemotherapy), and demographics 92
were provided by CCRG. Ethical approval was obtained from the relevant Multi-Centre 93
Research Ethics Committee and every Local Research Ethics Committee in Britain (212 in 94
total).  95
 96
Death ascertainment 97
Deaths among childhood cancer survivors were ascertained by linking the BCCSS cohort 98
with the National Health Service Central Registers. Such linkage of the entire population-99
based cohort with the national population-based death registration system provides a means 100
of ascertaining when each survivor dies. For each death an attempt was made to obtain the 101
death certificate and underlying cause of death as coded by the Office of National Statistics 102
using the appropriate chronological revision of the International Classification of Diseases. 103
The level of specificity used to classify underlying causes of death was determined a priori 104
and corresponded to the principal sections of the relevant revisions of the International 105
Classification of Diseases. Whenever the underlying cause of death was neoplastic, the 106
death certificate and other available sources were examined to decide whether the death 107
was due to recurrence or progression of the original cancer, or in fact due to a second 108
primary cancer. Follow-up of cohort members for mortality started at the date of five-year 109
5survival beyond the time of initial childhood cancer diagnosis. The cohort exit date was 31 110
December 2006 with earlier exits at death or loss-to-follow-up. 111
 112
Statistical analysis 113
Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were calculated for 114
each specific cause of death using standard cohort techniques.10 The SMR was defined as 115
the ratio of the observed over the expected number of deaths. The AER was defined as the 116
observed minus the expected number of deaths divided by the number of person-years at 117
risk multiplied by 10,000. The AER is a useful measure for determining the additional 118
mortality burden beyond the background mortality as it reflects the number of excess deaths 119
per 10,000 persons per year. To derive the expected number of deaths used in the 120
calculation of the SMR and AER, person-years for each sex, age (5-year bands) and 121
calendar year (1-year bands) specific stratum were multiplied by the corresponding mortality 122
rate for the England & Wales population and then summed across the strata.11 For causes of 123
death that exceeded 100 observed deaths, SMRs and AERs were stratified by the following 124
factors: sex, type of childhood cancer, age at childhood cancer diagnosis (0-4, 5-9, 10-14 125
yr), treatment with radiotherapy (yes/no), treatment with chemotherapy (yes/no), years from 126
diagnosis (5-14, 15-24, 25-34, 35-44 and !45 yr) and attained age (0-19, 20-29, 30-39, 40-127
49, and !50 yr).To evaluate the simultaneous effect of the above-mentioned factors on the 128
SMR and AER, special multivariable Poisson regression models were used to derive relative 129
risks (RR) and excess mortality ratios (EMR) (see online Appendix). 130
 Derivation of SMRs for deaths due to recurrence would not be appropriate because 131
the corresponding mortality rate in the general population would be zero. However, the AER 132
corresponds to the crude mortality rate for recurrence, and we stratified these mortality rates 133
by the factors sex, type of childhood cancer, age at diagnosis (0-4, 5-9, 10-14 yr), treatment 134
with radiotherapy (yes/no), treatment with chemotherapy (yes/no), years from diagnosis (5-135
14, 15-24, 25-34, 35-44 and !45 yr) and attained age (0-19, 20-29, 30-39, 40-49, and !50 136
6yr). The simultaneous effects of these factors on the mortality rate were evaluated by 137
employing a multivariable Poisson regression model (see online Appendix). 138
Cumulative mortality, as a function of years since diagnosis, for death causes 139
exceeding 100 deaths was estimated by means of the stcompet command in Stata.12 140
Causes of death other than the one under study were treated as competing risks. Stata 141
statistical software was used for all analyses.13 The criterion for statistical significance was a 142
two-sided p-value of less than 0.05.143
7Results 144
Cohort characteristics 145
Of the 17,981 five-year survivors in the cohort, 3,049 (17.0%) had died, 245 (1.4%) were lost 146
to follow-up, and 14,687 (81.7%) were alive at the study exit date. Death certificates were 147
obtained for 3,035 out of the 3,049 (99.5%) deaths. Nearly half of the cohort (47.4%) had 148
survived 25 years or more from diagnosis of their childhood cancer, with 32% having 149
survived more than 30 years. Survivors were followed-up for a total of 370,025 person-years 150
from 5-year survival with a mean follow-up of 20.6 years. There were 134,727 and 83,783 151
person-years beyond 20 and 25 years from diagnosis, respectively, and 34,345 person-152
years beyond age 40.  153
154
Overall observed and expected number of deaths 155
The SMR was significantly increased for all causes of death, except for mental disorder 156
related deaths and suicide (Table 1). A substantial excess (SMR>=5) was apparent for 157
deaths due to genitourinary disease, respiratory disease, infection, second primary cancer, 158
blood disease, and cerebrovascular disease. In terms of absolute excess risk, survivors 159
were most at risk of dying of recurrence (AER=51.8), second primary cancer (AER=11.3), 160
circulatory disease (AER=3.4) and respiratory disease (AER=2.5). 161
 162
All causes of death combined – potential risk factors 163
Overall, survivors experienced 11 times the number of deaths expected from the general 164
population (SMR=10.7, 95% confidence interval [CI] = 10.3-11.1) and 75 additional deaths 165
per 10,000 per year in excess of that expected (Table 2). The SMR declined significantly 166
with increasing follow-up and attained age (Ptrend<.0001); nonetheless, significant excess 167
mortality remained even after 45 years from diagnosis (SMR=3.1, 95%CI=2.5-3.9). There 168
was evidence of non-linearity in AERs by follow-up (Pnon-lineaity<.0001); with the variation in 169
the AER resembling a U-shaped curve. The AER was 115 over the first 10 years after 5-year 170
8survival, declined to roughly 40 between 15 and 35 years after diagnosis, and then 171
increased back up to 114 beyond 45 years after diagnosis. All types of childhood cancer 172
were associated with significantly increased mortality relative to the general population, with 173
the greatest SMRs observed among survivors of primitive neuroectodermal tumor (PNET) 174
and leukemia. The AER was 192 after PNET and also exceeded 100 after CNS tumors other 175
than PNET and after leukemia (other than AML).  176
 177
Specific causes of death - potential risk factors 178
The crude mortality rate for recurrence, which may be interpreted as an AER, decreased 179
rapidly from almost 100 at 5-14 years from diagnosis to less or equal to 11 deaths per 180
10,000 survivors per year beyond 25 years from diagnosis (Table 2). Mortality due to 181
recurrence or progression of the original disease was greatest among PNET survivors. 182
Females were at significantly lower risk than males (RR=0.8, 95%CI= 0.8-0.9) (eTable1). 183
The SMR for a second primary cancer declined sharply up to 35 years after 184
diagnosis, but thereafter remained at a roughly constant level (Table 2). Even after 45 years, 185
the SMR was still 3.6-fold (95% CI=2.6-4.9). Similarly, the SMR decreased significantly with 186
attained age (Ptrend<.0001), but still was elevated 3-fold beyond age 50. In contrast, the AER 187
increased with time since diagnosis and attained age reaching 58 beyond 45 years from 188
diagnosis and 39 beyond age 50. Beyond 45 years, over 51% of the total absolute excess 189
risk could be attributed to deaths due to a second primary cancer (Table 3). The SMR was 190
significantly elevated for all types of childhood cancer, but greatest among survivors of 191
PNET and heritable retinoblastoma. Treatment with radiotherapy increased both the RR and 192
EMR 2-fold (eTable 1). 193
The SMR for circulatory deaths, which includes cardiac and cerebrovascular deaths, 194
was 11-fold over the first 10 years of follow-up and then declined to a plateau and remained 195
roughly at 2 to 3-fold beyond 25 years from diagnosis (Table 4). On the other hand, the AER 196
for circulatory deaths increased steadily with follow-up (Ptrend<.0001) reaching 29 beyond 45 197
years from diagnosis. Nearly 26% of all excess deaths beyond 45 years from diagnosis were 198
9attributed to circulatory causes (Table 3). All survivors, apart from retinoblastoma and bone 199
tumor survivors, exhibited significantly elevated SMRs for circulatory disease. The AER 200
exceeded 10 for survivors of AML. Multivariable analyses revealed that survivors treated 201
with radiotherapy were at a 2-fold significantly increased risk of dying of circulatory disease 202
relative to survivors not treated with radiotherapy in terms of both RR and EMR (eTable 2). 203
The SMR for cardiac disease declined with increasing follow-up, but remained 2-fold 204
elevated 45 years after diagnosis (Table 4). The AER increased significantly (Ptrend=.01) with 205
follow-up, reaching 15 beyond 45 years from diagnosis. The SMR and AER was greatest for 206
survivors of AML. Thirteen percent of all excess deaths beyond 45 years from diagnosis 207
were attributed to cardiac causes (Table 3). 208
The SMR for respiratory disease declined with increasing follow-up, but remained 209
significantly elevated even 45 years after the initial cancer diagnosis (Table 4). In contrast, 210
the AER increased significantly with increasing time since diagnosis to an AER of 8.5 211
beyond 45 years from diagnosis. Survivors of all cancer types, apart from those with non-212
heritable (NH) retinoblastoma or a bone tumor, exhibited significantly elevated SMRs for 213
respiratory disease. Survivors treated with chemotherapy were at 3-fold increased risk 214
versus those not treated with chemotherapy, in terms of both RR and EMR (eTable 2).  215
The SMR for external causes of death increased slightly with follow-up, to an SMR of 216
3.0 beyond 45 years from diagnosis (Table 4). The AER also increased slightly with follow-217
up.  218
Cumulative mortality 219
The cumulative mortality (CM) from all death causes, other than recurrence, was 28.0% at 220
55 years from initial diagnosis whereas 8.7% was expected based on rates from the general 221
population (Figure 1). The CM of death due to recurrence increased rapidly with time from 222
diagnosis to 8.9% by 15 years; but then leveled off reaching 12.4% by 50 years (Figure 1). 223
The CM of second primary cancer increased gradually with time from diagnosis reaching 224
2.4% by 30 years, but then increased rapidly up to 13.4% by 55 years (Figure 1). For 225
10 
circulatory deaths, the CM was low by 30 years (CM=0.8%), but increased substantially up 226
to 6.1% by 55 years from diagnosis (Figure 1).  227
 228
229
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Discussion230
Previously no study has satisfactorily investigated the cause-specific mortality of survivors of 231
childhood cancer beyond 25 years after the initial cancer diagnosis. This study, the largest 232
ever in terms of accumulated person-years and number of deaths, identified that there is a 233
persistence of an elevated risk of mortality due to second primary cancer, circulatory, and 234
pulmonary disease beyond 25 years from diagnosis relative to the general population. As a 235
result of this elevated relative risk, the absolute excess risk of mortality due to second 236
primary cancer, circulatory disease, and pulmonary disease increases rapidly with increasing 237
time from diagnosis. The AER for deaths from recurrence declined from 97 extra deaths (per 238
10,000 per year) at 5-14 years from diagnosis to 8 extra deaths beyond 45 years from 239
diagnosis. In contrast during the same periods of follow-up the AER for deaths from second 240
primary tumor, circulatory deaths and cardiac deaths increased from 8, 2 and 1 extra deaths 241
to 58, 28 and 15 extra deaths, respectively. Beyond 45 years from diagnosis recurrence only 242
amounts for 7% of the excess number of deaths observed whilst second primary cancers 243
and circulatory deaths together account for 77%.  244
Previously, we have reported the risks of specific causes of death after childhood 245
cancer within the same cohort 3, 5, but the current study adds 16 years of follow-up and 1,507 246
deaths for analysis. The Childhood Cancer Survivor Study (CCSS)2 and a cohort from the 247
Nordic Countries4 were of similar size as the current cohort, but had fewer person-years and 248
observed deaths, particularly beyond 25 years from diagnosis. Compared with these two 249
studies, our SMRs by follow-up were generally consistent, although somewhat higher than 250
those in the Nordic Country Study and marginally lower than observed in the non population-251
based CCSS. In all three studies, however, the cumulative mortality of second primary 252
cancer by 25 years from diagnosis was low (<3.5%); but in the current study it increased 253
substantially (>13%) in the subsequent years of follow-up and such older survivor 254
experience is only available to the current study. The AERs by follow-up for second primary 255
cancer, cardiac, and respiratory causes were comparable between the CCSS and BCCSS. If 256
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the AER in the CCSS were to increase over the next few decades in a similar fashion as in 257
the current cohort, a substantial number of survivors would die prematurely. 258
It is interesting to note that there was no increase in deaths from suicide or other 259
mental disorders. Whilst there are concerns about long term psychological problems for 260
some survivors of childhood cancer, this does not appear to lead to an excess of deaths 261
from these causes. 262
The excess mortality due to second primary cancer and circulatory disease is likely 263
attributable to late complications of treatment. Second primary cancers are a recognized late 264
complication of childhood cancer14-16 largely due to exposure to radiation during treatment, 265
but specific cytotoxic drugs also have been implicated in the development of second primary 266
cancers. In addition, a small proportion of all second primary cancer deaths might be related 267
to familial cancer syndromes, such as Li-Fraumeni and heritable retinoblastoma.17 Evidence 268
is also emerging that treatment of childhood cancer increases the risk of circulatory 269
disease.18 More specifically, exposure to cranial irradiation increases the risk of stroke19-20 270
and exposure to chest irradiation has been associated with heart disease18, but also 271
exposure to high cumulative doses of specific chemotherapeutic agents, principally the 272
anthracyclines, may induce cardiotoxicity.18, 21-23 273
A potential limitation of our study includes the lack of detailed data on radiotherapy 274
and chemotherapy exposures which precluded any examination of dose-response patterns 275
of treatment exposures in relation to mortality risk. It is further important to acknowledge that 276
survivors included in the current cohort were treated between 1940 and 1991; consequently, 277
findings may not be translatable to survivors treated in more recent years. Also, the mortality 278
risks we provide for survivors followed-up for more than 30 years, and who were thus treated 279
prior to the introduction of modern anti cancer therapy, may not be applicable to survivors 280
treated with modern therapy including, for example, chemotherapy. Further follow-up is 281
necessary to address with more certainty the mortality risk of survivors treated in more 282
recent decades. 283
13 
The large-scale population-based ascertainment of deaths in this cohort ensures 284
provision of unbiased and reliable risk estimates of late mortality among survivors of 285
childhood cancer. Such risk estimates are useful for informing survivors and clinicians 286
regarding the risk of late-death. In light of the rapid and progressive increase in AER by time 287
since diagnosis continued monitoring of mortality patterns among long-term survivors of 288
childhood cancer would be prudent, particularly as increasing numbers of survivors reach an 289
age at which the risk of mature onset diseases increases substantially in the general 290
population. There is clearly potential for an increasingly substantial number of premature 291
deaths among survivors. 292
In terms of absolute risk, survivors diagnosed more than 25 years ago are currently 293
the most at risk of dying of a second primary cancer or circulatory disease, yet these 294
survivors are much less likely to be on active hospital follow-up than those diagnosed more 295
recently 24. The findings of this study suggest that survivors should be able to access health 296
care intervention programmes even many years after survival from their first cancer. 297
In conclusion, the findings from this largest ever population-based study of its kind 298
indicate that the absolute excess risk and cumulative mortality related to second primary 299
tumors, circulatory, and respiratory disease increases rapidly beyond 25 years from 300
diagnosis which suggests a substantial number of survivors are dying prematurely. These 301
findings confirm the importance of very long-term outcome data and that survivors should be 302
able to access health care programmes even decades post treatment. Finally, the principal 303
clinical message from these data is straightforward; 77% of the excess number of deaths 304
observed among those surviving beyond 45 years from diagnosis of childhood cancer in 305
Britain are due to second primary cancers and circulatory deaths. Finding ways to 306
successfully intervene to reduce these potentially preventable premature deaths will be 307
complex.308
309
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Figure 1. Cumulative mortality for each cause of death taking into account other causes of death as a competing risk 
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Table 1. Observed and expected deaths, standardized mortality ratio (SMR), and absolute 
 excess risk (AER) of specific causes of death
 Observed Expected SMR 95%CI AER* 
All causes 3049 284.8 10.7 (10.3, 11.1) 74.9 
Recurrence/progression disease 1918 0 NA NA 51.8 
All causes except recurrence 1117 284.8 3.9 (3.7-4.1) 22.4 
Second primary cancer 483 66.4 7.3 (6.7, 8.0) 11.3 
All non-neoplastic causes 634 218.4 2.9 (2.7-3.1) 11.1 
Infections 44 5.9 7.5 (5.4,10.0) 1.0 
Blood disease 7 1.3 5.4 (2.2,11.2) 0.2 
Endocrine disease 24 6.2 3.9 (2.5, 5.7) 0.5 
Mental disorders 7 8.5 0.8 (0.3, 1.7) 0.0 
Nervous system disease 55 13.5 4.1 (3.1, 5.3) 1.1 
Circulatory (all) disease 170 43.0 4.0 (3.4, 4.6) 3.4 
--Cardiac disease 105 29.9 3.5 (2.9, 4.2) 2.0 
--Cerebrovascular disease 48 9.0 5.2 (3.9, 6.9) 1.0 
--Circulatory disease other 17 4.0 4.3 (2.7, 6.9) 0.4 
Respiratory disease 106 13.3 8.0 (6.6, 9.7) 2.5 
Digestive disease 30 14.3 2.1 (1.4, 3.0) 0.4 
Skin and musculoskeletal disease 5 1.5 3.3 (1.1, 7.6) 0.1 
Genitourinary disease 21 2.0 10.6 (6.6, 16.3) 0.5 
Pregnancy and childbirth  17 6.5 2.6 (1.5, 4.2) 0.3 
External causes 138 99.6 1.4 (1.1, 1.6) 0.9 
--Suicide 37 37.6 1.0 (0.7-1.4) 0.0 
Other 10 2.7 3.7 (2.0, 6.8) 0.2 
* Per 10,000 survivors per year 
NA, Not applicable 
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Table 3. Absolute excess risk (AER) by years from diagnosis as a proportion of total absolute excess risk 
Years from diagnosis (yrs) 
Cause of death 5-14 15-24 25-34 35-44 45+ 
AER AER AER AER AER 
Recurrence
*
96.6 (84.9%) 18.9 (50.1%) 11.1 (26.7%) 9.0 (17.3%) 8.2 (7.2%) 
Second primary cancer 8.2 (7.2%) 10.3 (27.3%) 14.3 (34.5%) 21.8 (42.0%) 58.0 (51.0%) 
Circulatory 2.1 (1.9%) 2.9 (7.4%) 4.6 (11.1%) 7.5 (14.5%) 29.4 (25.9%) 
 Cardiac 1.4 (1.2%) 1.9 (4.8%) 3.0 (7.2%) 2.5 (4.8%) 15.1 (13.3%) 
Respiratory 2.5 (2.2%) 1.3 (3.5%) 3.4 (8.2%) 5.9 (11.4%) 8.5 (7.4%) 
External 0.6 (0.3%) 0.7 (1.9%) 2.4 (5.8%) 1.9 (3.7%) 5.5 (4.8%) 
Other  3.9 (3.4%) 3.7 (9.8%) 5.7 (13.7%) 5.8 (11.1%)  4.1 (3.6%) 
      
All deaths
†
113.9 37.8 41.5 51.9 113.7 
*
 Expected number for deaths due to recurrence assumed to be zero  
†
Small inconsistency of total AER with AER from Table 2 is due to unknown causes of death amongst 14 survivors.
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